¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑ ÆÄŲ½¼º´ ¹× ÀÌ»ó¿îµ¿Áúȯ ÇÐȸ(KMDS) 2021 Ãá°èÇмú´ëȸ : 2021-04-10

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇÑ ÆÄŲ½¼º´ ¹× ÀÌ»ó¿îµ¿Áúȯ ÇÐȸ(KMDS) 2021 Ãá°èÇмú´ëȸ : 2021-04-10
±³À°ÀÏÀÚ : 2021-04-10
±³À°Àå¼Ò : ÀÓÇǸ®¾óÆÓ¸®½º È£ÅÚ ¼­¿ï  
±³À°ÁÖÁ¦ : ´ëÇÑ ÆÄŲ½¼º´ ¹× ÀÌ»ó¿îµ¿Áúȯ ÇÐȸ(KMDS) 2021 Ãá°èÇмú´ëȸ      
ÁÖÃÖ±â°ü : ´ëÇÑÆÄŲ½¼º´¹×ÀÌ»ó¿îµ¿ÁúȯÇÐȸ
´ã´çÀÚ : ±è½Ã¿ø
¿¬¶ôó : 02-6395-2876  
À̸ÞÀÏ : movement@kmds.or.kr      
±³À°Á¾·ù : ½Å°æ°ú      
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 5Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 50ºÐ  
¼¼ºÎ¼ö°­·á : 30,000¿ø      
ºñ°í Á¤È¸¿ø 30,000¿ø / ÁØȸ¿ø 20,000¿ø / ºñȸ¿ø 40,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-10 ¸Þ±×·¹Ã÷¾Ë¸®¿ÀÃ÷ 09:00~09:40 alpha-synuclein pathology in the skin  Charles Adler(Mayo Clinic, USA) 
±³À°½Ã°£ 04-10 ¸Þ±×·¹Ã÷¾Ë¸®¿ÀÃ÷ 09:40~10:10 Neuromodulation in PD and neurodegnerative diseases  ¿ÀÀÀ¼®(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 04-10 ¸Þ±×·¹Ã÷¾Ë¸®¿ÀÃ÷ 10:10~10:40 Recent clinical trials in PD: positive and negative  Ãµ»ó¸í(µ¿¾ÆÀÇ´ë) 
È޽Ġ04-10  10:40~10:50 È޽Ġ () 
±³À°½Ã°£ 04-10 ¸Þ±×·¹Ã÷¾Ë¸®¿ÀÃ÷ 10:50~11:20 The link between two pathogenic mechanisms: synucleinopathy and inflammation in PD  ±è¿µÀº(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 04-10 ¸Þ±×·¹Ã÷¾Ë¸®¿ÀÃ÷ 11:20~11:50 GBA, lysosome and PD  Ç㿵Àº(Â÷ÀÇ°úÇдë) 
È޽Ġ04-10  11:50~12:00 È޽Ġ () 
±âŸ 04-10 ¸Þ±×·¹Ã÷¾Ë¸®¿ÀÃ÷ 12:00~13:00 ÃÑȸ ¹× Á¡½É½Ä»ç  ±Çµµ¿µ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 04-10 ¸Þ±×·¹Ã÷¾Ë¸®¿ÀÃ÷ 13:00~13:30 Autonomic dysfunction in PD: pathophysiology and management  ¿ÀÀ±»ó(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 04-10 ¸Þ±×·¹Ã÷¾Ë¸®¿ÀÃ÷ 13:30~14:00 Update in medical treatment for PD  ÀÌÁöÀº(±¹¹Î°Ç°­º¸Çè°ø´ÜÀϻ꺴¿ø) 
±³À°½Ã°£ 04-10 ¸Þ±×·¹Ã÷¾Ë¸®¿ÀÃ÷ 14:00~14:30 Iron-sensitive MRI in parkinsonism  ÀÌÀçÇõ(ºÎ»êÀÇ´ë) 
È޽Ġ04-10  14:30~14:40 È޽Ġ () 
±³À°½Ã°£ 04-10 ¸Þ±×·¹Ã÷¾Ë¸®¿ÀÃ÷ 14:40~15:10 iRBD and syncleinopathy  ÀÌÁö¿µ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04-10 ¸Þ±×·¹Ã÷¾Ë¸®¿ÀÃ÷ 15:10~15:40 Rare genetic disorders with parkinsonism  Àå¿ì¿µ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 04-10 ¸Þ±×·¹Ã÷¾Ë¸®¿ÀÃ÷ 15:40~16:20 Heterogeneity of PD  Robert de Bie(Amsterdam UMC) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑ ÆÄŲ½¼º´ ¹× ÀÌ»ó¿îµ¿Áúȯ ÇÐȸ(KMDS) 2021 Ãá°èÇмú´ëȸ : 2021-04-10""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) ´ëÇÑ ¼Ò¾Æ¾Ë·¹¸£±â È£Èí±âÇÐȸ Æó·ÅÈ£Èí±â¿¬±¸È¸-Áúº´°ü¸®Ã» ÈÄ¿ø½ÉÆ÷Áö¿ò : 2021-04-10
´ÙÀ½±Û Á¶¼±´ëÇб³º´¿ø 2021 ´ëÇѼºÇü¿Ü°úÇÐȸ ±¤ÁÖÀü³²Áöȸ Ãß°èÇÐȸ : 2021-04-09
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20820 ¼­¿ï ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ – Á¦31ȸ °³¿øÀǸ¦ À§ÇÑ ¿¬¼ö°­Á : 2024-06-16 0 4 2024-05-27
20819 ºÎ»ê ´ëÇÑÀ̽ÄÇÐȸ 2024³â ½ÅÀåÀÌ½Ä ½ÉÆ÷Áö¾ö : 2024-06-16 0 2 2024-05-27
20818 Á¦ÁÖ ´ëÇѳ»ºÐºñÇÐȸ Á¦22ȸ ºÐ°úÀü¹®ÀÇ ¿¬¼ö°­Á : 2024-06-16 0 3 2024-05-27
20817 ¼­¿ï ¼Ò¾Æû¼Ò³âÇൿ¹ß´ÞÁõÁø ¾ð¾î°Ë»ç ÇÁ·Î±×·¥ ¿öÅ©¼ó : 2024-06-16 0 1 2024-05-27
20816 ¼­¿ï Á¦28ȸ ¼­¿ï½Ã³»°úÀÇ»çȸ Á¤±âÃÑȸ ¹× Çмú´ëȸ : 2024-06-16 0 5 2024-05-27
20815 ¼­¿ï 2024³â Á¦16ȸ °æÈñ´ëÇб³º´¿ø ¼ÒÈ­±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-06-16 0 0 2024-05-27
20814 ºÎ»ê 2024 ´ëÇÑ ¼Ò¾Æ¾Ë·¹¸£±â È£Èí±âÇÐȸ ¿µ³²¼Ò¾Æ¾Ë·¹¸£±â ½ÉÆ÷Áö¿ò : 2024-06-16 0 2 2024-05-27
20813 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø Á¦23Â÷ ½Å»ý¾Æ¼Ò»ý¼ú workshop : 2024-06-16 0 0 2024-05-27
20812 ¼­¿ï 2024³â ´ëÇÑÀÇÇÐÀ¯ÀüÇÐȸ ÀÇÇÐÀ¯ÀüÇÐ Primer Course : 2024-06-16 0 3 2024-05-27
20811 ¼­¿ï 2024 ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-15 0 2 2024-05-27
20810 ¼­¿ï ´ëÇÑÁ¤Çü¿Ü°ú ÄÄÇ»Åͼö¼úÇÐȸ - Á¦3ȸ ±¹Á¦ ·Îº¿¼ö¼ú ½ÉÆ÷Áö¾ö : 2024-06-15 0 5 2024-05-27
20809 °æ±â ´ëÇѺñ¸¸ÇÐȸ Á¦18ȸ ODOT (One Day Course of Obesity Treatment) : 2024-06-15 0 4 2024-05-27
20808 ¼­¿ï 2024³â Á¦ 1ȸ ºñ¸¸ ¿¬¼ö°­ÁÂ(ObesityCare Pro) : 2024-06-15 0 4 2024-05-27
20807 ¼­¿ï 2024 °¡Å縯´ëÇб³ ÀºÆò¼º¸ðº´¿ø ½Å°æ¿Ü°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-06-15 0 3 2024-05-27
20806 ¼­¿ï ´ëÇѼöºÎ¿Ü°úÇÐȸ ¼öºÎ»óÁö ÇÏ°èÇмú´ëȸ : 2024-06-15 0 3 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷